Vector Centers COVID-19 Vaccine Is Safe for People with Allergies and Seniors

26 October 2020

GMP News

The Vector State Research Center of Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing has detected over 80 mutations of the coronavirus yet they do not affect the effectiveness of the developed vaccine, the center’s General Director Rinat Maksyutov reported on Wednesday (October 21).

“The Vector Center is additionally conducting extensive studies of the genetic variability of the novel coronavirus in all Russian regions. <…> We constantly perform whole-genome sequencing and detect possible mutant variants. To date, we have detected over 80 nucleotide substitutions which are not included in international databases. But these changes are not critical and do not influence the effectiveness of the peptide vaccine developed,” he said at the 17th annual meeting of the Valdai International Discussion Club.

The coronavirus vaccine developed by Siberia’s Vector Center is safe for people with allergies or chronic conditions and seniors, the general director of the center said Wednesday. “The vaccine is fully safe both for healthy volunteers, people with chronic conditions or allergies and seniors.”

The trials showed that the vaccine has high immunogenicity properties. “We confirmed that the peptide vaccine showed both the high safety profile and high immunogenicity in the conducted clinical trials involving 100 volunteers as all volunteers who received the shot had an immune response. This sampling gives us proof of the protective effectiveness in the framework of the conducted epidemiological research,” Maksyutov pointed out.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more